title: A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain).
abstract: CMV-seronegative subjects vaccinated intramuscularly or intradermally with a DNA vaccine encoding pp65, IE1, and gB were administered live-attenuated CMV (Towne) to characterize immune priming by the DNA vaccine. CMV-specific memory T-cells (detected by standard ELISPOT assay in only 20% of subjects) were detected by IFN-gamma cultured ELISPOT assay in 60% of subjects primed intramuscularly and correlated with immune responses after Towne. The median time to first pp65 T-cell and gB antibody response after Towne was 14 days for DNA-primed subjects vs. 28 days for controls administered Towne only (p=0.02 and 0.03, respectively). Furthermore, there was a trend toward more DNA-vaccinated subjects than controls developing a gB-specific IFN-gamma T-cell response after Towne administration (47% vs. 0%, p=0.06).
authors.affiliation: Positive Health Program, Department of Medicine, University of California San Francisco, 4th Floor, 995 Potrero, San Francisco, CA 94110, United States. mjacobson@php.ucsf.edu
authors.forename: Mark A
authors.initials: MA
authors.lastname: Jacobson
authors.forename: Stuart P
authors.initials: SP
authors.lastname: Adler
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Sinclair
authors.forename: Douglas
authors.initials: D
authors.lastname: Black
authors.forename: Anna
authors.initials: A
authors.lastname: Smith
authors.forename: Alice
authors.initials: A
authors.lastname: Chu
authors.forename: Ron B
authors.initials: RB
authors.lastname: Moss
authors.forename: Mary K
authors.initials: MK
authors.lastname: Wloch
mesh_terms: D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D000956:Antigens, Viral; D003587:Cytomegalovirus / Q000276:immunology*; D022482:Cytomegalovirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D005260:Female; D006801:Humans; D007156:Immunologic Memory; D066298:In Vitro Techniques; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000096:biosynthesis; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D022482:Cytomegalovirus Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D007371:Interferon-gamma